HIV Seropositivity Clinical Trial
Official title:
Community-based Distribution of Oral HIV Self-testing Kits-A Pilot Intervention and Rapid Impact Evaluation
This cluster randomised trial aims to evaluate the impact of a pilot HIVST intervention of
oral HIV self-testing (HIVST) as an option for HIV testing, in addition to the offer of
home-based rapid HIV testing, through community health workers (CHW) on knowledge of HIV
status among the general adult and adolescent population.
The primary outcome of the trial is the proportion of individuals who know their HIV status,
defined as a self-report of being HIV positive or accepting testing (standard or self
testing) from the CHW.
Embedded within the impact evaluation is a process evaluation that will explore the fidelity
of the implementation of the intervention and outputs of the intervention. Qualitative data
on actual use, management and disposal of the HIVST kits, acceptability of HIVST and any
impacts on relationships (including between couples and with CHW) associated with use of
HIVST kits.
Trial Purpose This cluster randomised trial will evaluate the impact of a pilot intervention
of oral HIV self-testing (HIVST) as an option for HIV testing, in addition to the offer of
home-based rapid HIV testing, by community health workers (CHWs ) on knowledge of HIV status
among the general adult and adolescent population.
Aim The overall aim of this trial is to investigate whether the inclusion of HIVST as an
option for HIV testing, in addition to the offer of HIV testing with a finger-prick blood
sample, increases the uptake of an offer of home-based HIV-testing overall relative to an
offer of HIV testing with a finger-prick blood sample alone.
Secondary Objectives
1. Investigate whether the inclusion of HIVST as an option for HIV testing in addition to
the offer of HIV testing with a finger-prick blood sample through CHW increases the
uptake of an offer of HIV-testing among specific sub-populations including men,
adolescents and individuals who have not previously tested relative to an offer of HIV
testing with a finger-prick blood sample alone.
2. Investigate whether the inclusion of HIVST as an option for HIV testing in addition to
the offer of HIV testing with a finger-prick blood sample through CHW increases the
proportion of individuals' diagnosed HIV positive relative to an offer of HIV testing
with a finger-prick blood sample alone.
3. Measure linkage to HIV treatment and care, or prevention services when HIVST is included
as an option for HIV testing in addition to the offer of HIV testing with a finger-prick
blood sample through CHW and levels of couples-testing.
Trial Design This cluster randomised trial will randomise community health worker zones (66
in total) to either distribute oral HIVST kits in addition to the offer of finger-prick rapid
HIV testing (33 zones) or to offer finger-prick rapid HIV testing alone (33 zones). The trial
is nested within theHPTN071/PopART trial and the CHWs to be randomised all work in 4 of the
intervention sites of this study.
Trial location Four communities in the Copperbelt and Central province of Zambia have been
chosen to participate in this trial.
Trial Participants All adults and adolescents aged 16 years or older living in these
communities are eligible for participation if they consent to participate in the household
visit and are eligible for HIV testing (individuals aged 16 years or older who do not report
knowing their HIV status). The CHW will use the electronic data capture devices to collect
all information.
Process Evaluation Measures and Data Collection Process evaluation data will be collected
using standardised data collection forms developed for this trial, including forms to collect
data on how many CHW attended training on the demonstration of HIVST and the number of HIVST
kits procured. Data will also be collected on: 1). the number of households visited and
offered the option of HIVST or door-to-door rapid finger-prick HIV testing, and follow-up
visits to individuals receiving an HIVST kit(s). the number of community engagement
activities performed to inform the community of the availability of HIVST kits. Data on
number of households visited will be collected through the existing EDC devices with data on
community activities collected from routine monitoring data. Expected outputs, namely the
number of HIVST kits distributed for use by individuals present or absent at the time of the
household visit, will also be collected through the existing EDC devices. Data on outcomes of
interest will be collected through the existing EDC devices, with linkage data extracted
using forms developed for HPTN071 and qualitative data collection, including the
acceptability of HIVST and their distribution through CHW.
Measured as part of the Process Evaluation
The following measures will be estimated through qualitative and quantitative data collection
as part of the process evaluation:
Inputs:How many CHW were trained to deliver the intervention? How many HIVST kits were
procured? How many meetings with CABs, community mobilisers and other stakeholds were held?
And how many attendees were at these meetings? Activities: How many door-to-door visits were
conducted? How many communication activities were held in the communities? Outputs: How many
HIVST kits were distributed? Were communities aware of the HIVST intervention and where to
obtain HIVST kits?Was HIVST acceptable? How was it perceived by community members?
Ethical Considerations The trial will be conducted in accordance with Good Clinical Practice
guidelines, and all research staff will receive GCP training. The Ethics Committees to
approve this study will be the Biomedical Ethics Committee of the University of Zambia and
the ethics committee of the London School of Hygiene and Tropical Medicine.
In all communities, HIV testing will follow the Zambian national HIV testing guidelines, with
HIV testing services offered only to individuals aged 16 years or older and informed consent
for HTS obtained as per the Ministry of Health guidelines. Individuals will be informed of
the HTS process and have the right to decline HTS or provide written or verbal consent to HTS
. For individuals absent at the time of the household visit, an index HIV testing client will
be asked whether they agree to accept an HIVST on behalf of the absent household member and
to provide a demonstration on how to perform the test to this same individual. This
individual will be asked to sign an agreement statement, stating that they will only give the
self-test kit to their spouse/partner. The absent individual can decline/opt-out of using the
HIVST and this will be made clear to the individual accepting the HIVST.
Individuals who participate in any in-depth qualitative studies will be asked to provide
written informed research consent.
Potential Harms Despite the increased availability of HIV testing services, including the
door-to-door offer of home-based HIV testing, testing for HIV remains a sensitive issue
subject to stigma and discrimination. HIV self-testing provides individuals more
confidentiality and the opportunity to avoid the stigma of being seen to access HIV testing
services at a clinic. Nonetheless, self-testing may pose harms distinct from facility- or
community-based HIV testing strategies, including concerns of coercion to test.
To date, studies of the distribution of HIV self-tests by volunteer-counsellors in Malawi
have found a low incidence of harms. Some 3% of individuals reported feeling coerced into
self-testing, however, among this group of individuals, 92% were highly satisfied with
self-testing and 94% stated they would recommend self-testing to family/friends.
Despite little evidence for social harms in other settings, offering a female an HIV
self-test for her absent male partner may pose risks, including risk of gender based violence
or coercion to self-test. The CHiPs are trained in providing couples HIV testing and
counselling services and will only leave a self-test kit if it is clear that there is no
history of violence in the relationship. Women will also be informed that the CHiP can return
to counsel the couple on their HIV test result or to support conducting the oral HIV
self-test. The CHiPs will also be trained to ensure that the person they leave the test kit
with has demonstrated that they can read and understand the test instructions and are able to
instruct others to properly conduct an HIV self-test. Further, the CHiPs will also ensure
that the person they leave the test kit with understands the consequences of forced testing
and acknowledges that they will not force anyone to test using the kit. To avoid inadvertent
coercion by leaving an HIV self-test for an individual who refuses the offer of HIV-testing,
a self-test will only be left for individuals who consent to have a self-test left for them.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03661203 -
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
|
||
Completed |
NCT00381212 -
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05983536 -
The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
|
||
Recruiting |
NCT04832477 -
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
|
N/A | |
Active, not recruiting |
NCT04044586 -
HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
|
||
Completed |
NCT03218839 -
Evaluation of the PrePex Device for Rapid Scale-up of VMMC, Phase 3 Field Implementation Trial With HIV + Adult Males
|
N/A | |
Active, not recruiting |
NCT00797030 -
Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus
|
Phase 4 | |
Recruiting |
NCT04088916 -
Proviral DNA as a Target for HIV-1 Resistance Analysis
|
||
Completed |
NCT03367130 -
Improving Clinic Attendance for Medication Collection Among HIV Positive Individuals in Nepal
|
N/A | |
Completed |
NCT04849767 -
National Survey About Trajectory and Life Conditions of HIV Trans People in France
|
||
Completed |
NCT05674682 -
Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study
|
N/A | |
Recruiting |
NCT05174234 -
Precariousness and Sexual Vulnerability of People From Haiti Living With or Without HIV in French Guiana
|
||
Completed |
NCT00130819 -
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
|
Phase 2 | |
Active, not recruiting |
NCT04706624 -
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
|
N/A | |
Recruiting |
NCT03858478 -
Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST
|
Phase 4 | |
Completed |
NCT02154971 -
Assessment of Age-related Hearing Loss in HIV-1 Patients
|
||
Recruiting |
NCT03333083 -
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
|
Phase 3 | |
Recruiting |
NCT03311945 -
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
|
Phase 3 | |
Recruiting |
NCT03795415 -
ANRS12373 GUNDO SO - Evaluation of an Empowerment Program for WLHIV in Mali
|
||
Completed |
NCT01813292 -
Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine
|
N/A |